Trials / Completed
CompletedNCT00558493
Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients
Phase lV Study to Evaluate the Safety and Effectiveness of Switching Treatment From Lamivudine to Clevudine in the Chronic Hepatitis B Patients With Suboptimal Virologic Response During Lamivudine Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
A multi-center and open study to compare the safety and effectiveness of switching treatment from lamivudine to clevudine for 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clevudine | clevudine 30 mg qd for 24 seeks |
Timeline
- Start date
- 2007-11-01
- First posted
- 2007-11-15
- Last updated
- 2012-07-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00558493. Inclusion in this directory is not an endorsement.